Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XmAb541 |
| Synonyms | |
| Therapy Description |
XmAb541 is a bispecific antibody targeting CLDN6 and CD3 that redirects cytotoxic T-lymphocytes towards tumor cells expressing CLDN6, potentially resulting in increased tumor cell killing (J Clin Oncol 2025 43: 5_suppl, TPS652, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XmAb541 | XmAb-541|XmAb 541 | CD3 Antibody 119 CLDN6 Antibody 10 | XmAb541 is a bispecific antibody targeting CLDN6 and CD3 that redirects cytotoxic T-lymphocytes towards tumor cells expressing CLDN6, potentially resulting in increased tumor cell killing (J Clin Oncol 2025 43: 5_suppl, TPS652, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06276491 | Phase I | XmAb541 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | Recruiting | USA | 0 |